4 Undervalued Biotechnology Stocks for Friday, June 26
Discover the top 4 undervalued Biotechnology stocks for Friday, June 26 based on AAII’s Stock Grades.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Commentary & Analysis
3 Undervalued Biotechnology Stocks for Monday, May 25
Discover the top 3 undervalued Biotechnology stocks for Monday, May 25 based on AAII’s Stock Grades.Tudor Pop
Why Atrium Therapeutics, Inc.’s (RNA) Stock Is Up 7.03%
As of Thursday, April 23, Atrium Therapeutics, Inc.’s RNA share price has surged by 7.03%, which has investors questioning if this is right time to sell.Michael Rose
Why Atrium Therapeutics, Inc.’s (RNA) Stock Is Down 5.50%
As of Friday, April 10, Atrium Therapeutics, Inc.’s RNA share price has dipped by 5.50%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Atrium Therapeutics, Inc.’s (RNA) Stock Is Down 6.10%
As of Wednesday, March 18, Atrium Therapeutics, Inc.’s RNA share price has dipped by 6.10%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | RNA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $207.1 | $269.0 | 28% |
|
| Shares Out (Mil) | 17.1 | 52.3 | 28% |
|
| Institutional Ownership | 96.5% | 92.2% | 70% |
|
| Float (Mil) | 15.7 | 39.8 | 26% |
|
| Beta | na | 0.93 | na |
|
| Avg Daily Volume (000s) | 122 | 488 | 38% |
|
| Price Change (52-week) |
na | 56.4% | na |
|
| Growth | RNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | RNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $37 | $38 | 17% |
|
| Net Income (TTM) (Mil) | ($59) | ($44) | 15% |
|
| EPS (TTM) | ($3.431) | ($1.600) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($61) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($43) | $182 | 1% |
|
| Valuation | RNA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.88 | 2.76 | 19% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | RNA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (32.9%) | 63.7% | 3% |
|
| Net Margin | (160.0%) | (70.3%) | 5% |
|
| ROA | (40.1%) | (50.0%) | 14% |
|
| ROE | (50.1%) | (57.5%) | 15% |
|
| Liabilities to Assets | 19.9% | 30.3% | 13% |
|
| F-Score | 0 | 3 | na |
|
Atrium Therapeutics, Inc. did not pass any screens on 8/6/2026.
